Gates and Chi­nese pri­vate eq­ui­ty group cheer on Lyn­dra's PhII plans with $55M raise

With back­ing from the Gates Foun­da­tion and some new Chi­nese pri­vate eq­ui­ty cash, Wa­ter­town, MA-based Lyn­dra has just pack­aged to­geth­er a $55 mil­lion fund­ing round to back their ex­pand­ed quest to kill the dai­ly pill ap­proach to meds.

Like dozens of com­pa­nies be­fore it, Lyn­dra got start­ed with some ideas hatched in the lab of MIT’s Bob Langer — and seed mon­ey from Po­laris. Now the biotech says that af­ter its first small hu­man proof-of-con­cept study wrapped last fall, they’re ready to move in­to Phase II with their first pro­gram fo­cused on a re­for­mu­lat­ed schiz­o­phre­nia ther­a­py de­signed to re­place a dai­ly reg­i­men with a long act­ing treat­ment with a much low­er bur­den on pill count.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.